Companies /Healthcare

CRISPR Therapeutics AG

NASDAQ: CRSP Biotechnology
$59.37
â–² $0.14 (+0.24%) today
Markets closed · 2:42am ET

Q2 2025 Earnings

Reported Aug 4, 2025, 4:21pm ET · SEC source
$-2.40
Miss −71.55%
EPS · est. $-1.40
$892,000
Miss −86.15%
Revenue · est. $6.4M
−4.4%
Trailing market
CRSP vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−10%−5%0+5%Aug 4Aug 5report 4:21pm ETearnings−0.7%−3.1%
−10%−5%0+5%Aug 4Aug 5earnings−0.7%−3.1%
CRSP −3.1%S&P 500 −0.7%
−10%−5%0+5%Aug 4Aug 5report 4:21pm ETearnings−1.1%−3.4%
−10%−5%0+5%Aug 4Aug 5earnings−1.1%−3.4%
CRSP −3.4%NASDAQ −1.1%
−4%0+4%Aug 4Aug 12report 4:21pm ETearnings+1.6%−0.2%
−4%0+4%Aug 4Aug 12earnings+1.6%−0.2%
CRSP −0.2%S&P 500 +1.6%
−4%0+4%Aug 4Aug 12report 4:21pm ETearnings+2.6%−0.2%
−4%0+4%Aug 4Aug 12earnings+2.6%−0.2%
CRSP −0.2%NASDAQ +2.6%
−6.71%
Day of report
+1.35%
Next session
+1.82%
One week
−1.31%
30 days

S&P 500 over the same 30 days: +3.07%.

Did CRSP Beat Earnings? Q2 2025 Results

CRISPR Therapeutics delivered a sharply disappointing second quarter, posting a loss of $2.40 per diluted share against a consensus estimate of $1.40, a miss of 71.55%, while revenue of $892,000 fell 86.15% short of the $6.44 million analysts had expected, though that modest top line still represented 72.5% growth year over year. The single largest driver of the quarter's wider loss was a $96.25 million charge for acquired in-process R&D tied to a new collaboration with Sirius Therapeutics on siRNA therapies, pushing the total net loss to $208.55 million. The results sent shares lower, even as the company pointed to accelerating momentum in its CASGEVY gene therapy launch, with 16 patient infusions completed in Q2 alone and reimbursement secured in 10 countries. Looking ahead, CRISPR expects complete Phase 1 data for its cardiovascular candidate CTX310, which has shown up to 82% triglyceride reductions, to be presented at a medical meeting in the second half of 2025, with additional pipeline updates for CTX112 and CTX131 also expected before year-end.

Key Takeaways
  • CASGEVY commercial ramp: 75+ ATCs activated globally, ~115 patients completed cell collection, 29 infused including 16 in Q2 2025
  • Reimbursement access secured in 10 countries for CASGEVY
  • Encouraging dose-dependent efficacy data from CTX310 Phase 1 trial
  • Expansion into siRNA modality via Sirius Therapeutics collaboration

“We are entering the second half of the year with momentum across both our commercial and clinical programs. The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance. Looking ahead, we expect several key milestones including the presentation of complete Phase 1 data for CTX310, as well as updates across our oncology and autoimmune portfolios. Our focus remains on delivering transformative therapies for patients with critical unmet needs.”

CRISPR Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

CRISPR Therapeutics expects several key milestones in the near term: complete Phase 1 data presentation for CTX310 at a medical meeting in H2 2025; broad updates for CTX112 in oncology and autoimmune diseases in H2 2025; CTX131 updates in 2025; CTX320 update in H1 2026; continued ramp of CASGEVY commercial launch with over 75 ATCs activated and growing patient infusions; an update on the regenerative medicine program (CTX211) in 2025; and advancement of a Phase 2 clinical trial of SRSD107 in Europe for thromboembolic disorders. The company also continues to advance next-generation approaches for SCD/TDT including anti-CD117 ADC conditioning and in vivo HSC editing to broaden addressable patient populations.

CRSP YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-600,000,000$-400,000,000$-200,000,000$0$517,012$892,000Revenue$-473,907,832$-229,324,000Operating Income$-595,513,992$-208,549,000Net Income
$-600,000,000$-400,000,000$-200,000,000$0RevenueOperating IncomeNet Income

CRSP Revenue by Segment

CASGEVY

Figures from SEC filings and company reports. Not investment advice.